EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection

Eric M. Kofoed, Terry D. Crawford, Christine M. Bowman, Jessica Sims, Tahnee J. Dening, Shumei Wang, Yuebiao Zhou, Seth F. Harris, Min Xu, Ping Wu, Ying Yang, Manda K. Wong, Racquel Corpuz, Yiming Xu, Anjani Ganti, Savita Ubhayakar, Chloe Hu, Kevin R. Clark, Zhijuan Cai, Kwong Wah Lai, Xiaojing Wang, Renwei Zhang, Michael F.T. Koehler, Emily J. Hanan, Ignacio Aliagas, Julie Ng, Jared Silverman, Khisimuzi Mdluli, Sharookh Kapadia, Man-Wah Tan

ACS Infectious Diseases · 2026-10-09 · 12 (10) · 3373-3384

DOI: 10.1021/acsinfecdis.6c00350 ↗
AbstractBibliografische Angaben

Abstract

Abstract Mycobacterium tuberculosis (Mtb) is responsible for more deaths per year than any other infectious disease. Resistance of circulating Mtb to the standard of care treatment regimen is an urgent global health crisis for which novel antibiotic treatments are needed. We have developed extremely potent, orally bioavailable, small-molecule inhibitors of inosine 5′-monophosphate dehydrogenase (GuaB) that catalyze the rate-limiting step in de novo guanine biosynthesis. The inhibitors exhibited bactericidal activity against Mtb in extracellular, intracellular, and hypoxic environments that capture features of advanced disease pathology in patients. Mtb GuaB2 inhibitors (GuaBi) were efficacious in three different in vivo mouse models of Mtb lung infection: the C57BL/6 super acute, C57BL/6 chronic, and C3HeB/FeJ (Kramnik) models. In the chronic BALB/c infection model of primarily intracellular Mtb, no benefit was observed, whereas in the C3HeB/FeJ model, a bedaquiline, pretomanid, and moxifloxacin treatment regimen that included GuaBi led to a rapid elimination of culturable Mtb infection in half of the mice. Notably, the C3HeB/FeJ model recapitulates advanced pathophysiology and heterogeneous disease that includes caseous necrotic granulomas, intracellular and extracellular reservoirs of Mtb, and lethal progressive infection. These results support further evaluation of a GuaBi-containing therapeutic regimen in relapse-capable preclinical models.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →